General Archives - Page 55 of 2367

1 minute read

Mirum Pharmaceuticals Gets Positive CHMP Opinion For LIVMARLI Oral Solution For The Treatment Of PFIC In Patients 3-Months Or Older

May 31, 8:39 AM

Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p<0.0001) reduction in pruritus severity between LIVMARLI vs. placebo across all PFIC types studied.CHMP assessment

MIRM

1 minute read

Why V.F. Corporation Shares Are Rising Today

By Nabaparna Bhattacharya

May 31, 8:38 AM

V.F. Corporation shares are rising in premarket trading following the announcement of Michelle Choe's appointment as Global Brand President of Vans, signaling potential growth and brand enhancement under her leadership.

GPS

2 minute read

Apple Set To Announce New AI Features At WWDC, But You Might Need At Least This iPhone To Use Them, Says Report

By Rounak Jain

May 31, 8:21 AM

Apple is set to unveil its AI strategy with Siri in focus, but users might need the latest top-tier iPhone 15 models to access all these features.

AAPL

1 minute read

Novartis Scemblix Phase III Data Shows Superior Efficacy With A Favorable Safety And Tolerability Profile Vs. Standard-Of-Care TKIs In Adults With Newly Diagnosed CML

By Benzinga Newsdesk

May 31, 8:20 AM

https://www.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml Phase

NVS

1 minute read

Gilead Sciences To Present EVOKE-01 Study Results In Metastatic NSCLC At An Oral Session At ASCO 2024

By Benzinga Newsdesk

May 31, 8:16 AM

– Simultaneously Published by the Journal of Clinical Oncology –Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract

GILD

1 minute read

Autolus Therapeutics Presents Additional Data Analysis Of Pivotal Phase 2 Felix Study Of obe-cel For Adult r/r B-all In An Oral Presentation At ASCO

By Benzinga Newsdesk

May 31, 8:11 AM

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem cell transplant

AUTL

1 minute read

Pfizer’s LORBRENA CROWN Study Shows Majority Of Patients With ALK-Positive Advanced Lung Cancer Living Beyond 5-Years Without Disease Progression

By Benzinga Newsdesk

May 31, 8:04 AM

An unprecedented 60% of patients remain alive without disease progression after five yearsUpdated results show continued 81% reduction in risk of progression or death and 94% reduction in progression of brain metastases

PFE

1 minute read

Blackstone Set To Acquire Japanese E-Comics Giant Infocom For $1.7B: Report

By Shivani Kumaresan

May 31, 7:47 AM

Blackstone is reportedly set to acquire a 55.1% stake in Japanese e-comics provider Infocom. Blackstone may aim to secure all of Infocom's shares through a takeover bid and share transfer. Blackstone manages $1.1 trillion in assets.

AIEQ